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This is a literature review and retrospective chart review of ten years experience on the treatment of
midcheek masses in our department. The purpose of this study is to provide the reader with an overview
of the pathology of this complex anatomic area focusing the attention on the differential diagnosis and
the recent surgical strategies.
From May 2002 to December 2012 we enrolled 22 consecutive patients studied for masses located in
the midcheek area. Only four studies were found in the literature describing the experience of individual
centres reporting few cases of midcheek masses. Combined with the previously reported 37 cases, we
describe 22 lesions for a total of 59 cases. Patients were evaluated with a head and neck clinical and
instrumental examination. Apart from 4 cases treated with intramuscular inﬁltration of botulinum toxin
for masseter hypertrophy, surgical approach to the lesions was varied: 10 patients received an external
approach (standard parotidectomy approach or face-lift-type approach); 6 patients had the lesion
removed through an intraoral approach; in 2 cases a direct skin incision was performed. In our series we
found a signiﬁcant rate (55.5%) of temporary complications in all the procedures performed (external,
intraoral, direct skin approach). This study aims to emphasize the role of endoscope assisted surgery as a
possible alternative to the traditional approaches for the management of well selected benign midcheek
masses.
It would be advisable to increase the study of the endoscopic anatomy of the midcheek area in order
to standardize the procedure and better deﬁne the surgical indications.
 2014 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights
reserved.1. Introduction
The term ‘‘midcheek’’ refers to a part of the midface on the
anterior aspect of the face, between the lower eye-lid above, and
the upper lip below.
Themidcheek is trapezoidal in shape, narrowing below, because
of the roundness of the cheek. Laterally the midcheek region is
bounded by an anterior concavity line, extending from the lateral
canthus to the labial commissure. This line passes over the body of
the zygomatic bone, the upper and anterior boundary of the
masseter muscle and the anterior portion of the buccinator muscle
(Mendelson and Jacobson, 2008)(Fig. 1).ansini 5, Naples 80131, Italy.
a@unina.it (G.D. Aversana
axillo-Facial Surgery. Published byThe peculiar anatomical location and the presence of so many
different structures in conﬁned spaces, makes this region a formi-
dable challenge for surgeons.
Pathology of this district is rare and the clinical evaluation of
masses in themidcheek region can be difﬁcult. Benign ormalignant
lesions in this area may arise from any number of the soft tissues
of the face, including skin, lymphatic, adnexal, neurogenic, and
salivary structures (Klotz and Coniglio, 2000). The differential
diagnosis for midcheek soft tissue masses includes Solitary
Vascular Malformations VMs (Cavernous hemangioma of APG,
Intramasseteric hemangioma, vascular leiomyoma), benign or
malignant lymphadenopathy, Masseter Muscle Hypertrophy, li-
pomas, neuroﬁbromas, schwannomas, neurilemmomas, ﬁbromas,
malignant tumors arising from the muscles, buccal fat pad, or other
structures, sialoceles, sialolithiasis and all benign and malignant
tumors araising fromAPGs. Benign ormalignant tumors originating
from the accessory parotid glands (APGs) or parotid gland proper
are among the most frequent diagnoses.Elsevier Ltd. All rights reserved.
Fig. 1. Midcheek has a trapezoidal shape, narrow below following of the roundness of
the cheek. Laterally, the midcheek region is limited by a line extending from the lateral
canthus to the labial commissure. This line passes over the body of the zygomatic bone,
the upper and anterior border of the masseter muscle and the anterior portion of the
buccinator muscle. PreZ, Prezygomatic space; ZN, Zygomatic nerve; BN, Buccal nerve;
APGs, Accessory Parotid Glands; BFP, Buccal fat pad.
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experience of some centres reporting a small number of cases of
midcheek masses (Table 1).
A total of 37 cases were described, the largest number arising
from the APGs (59.5%) (Klotz and Coniglio, 2000; De Riu et al., 2011;
Jung et al., 2010; Zhong et al., 2012).
The authors focus their attention on a speciﬁc disease, however,
there are still no reviews that describe all the midcheek masses.
This is a literature review and retrospective chart review of ten
years experience of midcheek mass treatment in our Department.
The purpose of this study is to provide the reader with an overview
about the pathology of this complex anatomic area focusing the
attention on the differential diagnosis and the recent surgical
strategies.
2. Material and Methods
The Authors conducted a retrospective study on our patient
database, analyzing all the cases treated in our department for
masses located in the midcheek area.
From May 2002 to December 2012 we treated 22 consecutive
patients (12 Females, 10 Males), with an average age of 38.8 years
(range 6 y to 76 y) (Table 2).
All patients were evaluated with a head and neck clinical and
instrumental examination. Apart from the presence of a progres-
sively enlarging mass, the patients were all asymptomatic. NoneTable 1
Midcheek mass literature review.
Year Author Patients n. APGs mass % Other mass %
2012 De Riu G et al. 9 77.8% 22.2%
2012 Zhong LP et al. 12 33.3% 66.7%
2010 Jung YH et al. 7 85.7% 14.3%
2000 Klotz DA et al. 9 55.5% 44.5%
Total 37 59.5% 40.5%complained of tenderness, difﬁculty chewing, or other head and
neck symptoms (Fig. 2).
A careful neck examination disclosed no enlarged node in any
patient. Sensation and facial nerve function were intact, and clear
saliva ﬂowed from the parotid duct in all cases. There was no evi-
dence of intraoral disease.
Patients underwent ultrasound investigations (US), computer-
ized tomography (CT) or magnetic resonance imaging (MRI) as well
as ﬁne-needle aspiration (FNAC) of the masses (Fig. 3a,b).
In three cases with masseter hypertrophy the diagnosis was so
clear that it was not necessary to perform the FNAC.
Masseter hypertrophy was treated with intramuscular inﬁltra-
tion of botulinum toxin (Botox).
Surgical approach to the lesions was varied: 10 patients received
an external approach (standard parotidectomy approach or face-
lift-type approach); 6 patients had the lesion removed through
an intraoral approach; in 2 cases a direct skin incision was per-
formed (Fig. 4aed).
Two cases of VMs received a selective embolization using
alcohol copolymer agents 24 h before surgery.
The course of disease of the sample ranged from 6 to 34 months
with a mean time period of 12.3 months.
3. Results
None of the patients receiving botulinum toxin for masseter
hypertrophy showed complications at a 6-months follow-up.
After surgical procedures, the most common complications
observed were hematoma, edema and temporary paralysis of the
buccal and zygomatic branches of the facial nerve.
Facial nerve palsy fully recovered in all cases within 6-months
after the intervention. In one case the paralysis of the buccal branch
of the facial nerve was permanent due to the entrapment of the
nerve in the neuroﬁbromatous lesion.
None of the patients with Pleomorphic adenoma of AGPs
experienced recurrence at a 22 months follow-up.
Although they were all reversible, in our series there was a high
complication rate (55.5%) in the approaches performed (Table 3).
4. Discussion
Only four studies in the literature describing the experience of
individual centres reporting few cases of midcheek mass were
found (Table 1). Adding our 22 cases with the previously reported
37 cases, results in a total of 59 cases observed to date.
An analysis of the cases described, showed that the most
frequent pathology of midcheek region arises from the APGs. Luksic
et al., 2012 reported 162 cases of tumors originating from the APGs.
These tumors are quite rare if considered alone; they account for 1e
8% of all parotid tumors but they should always be taken into ac-
count in midcheek mass differential diagnosis (Frommer, 1977;
Lewkowicz et al., 2000; Toh et al., 1993).
Differential diagnosis of a mass in the midcheek region can be a
very difﬁcult task. In our sample all patients were referred with a
history of progressive enlarging and painless mass in the midcheek
area. Head and neck clinical examination allowed us to guide the
diagnostic choices in all patients. Klotz and Coniglio (2000)
demonstrated that an accentuation of the mass on clenching the
teeth was evident in all the case of Masseter muscle hypertrophy.
Zhong et al. (2012) have reported that a change in size of the mass
with the posture is suspect for a Solitary Vascular Malformations
(VMs). The prevalence of VMs in midcheek area is second in fre-
quency only to APG masses. According to Zhong et al. (2012) a
Doppler ultrasound (US) is useful in order to obtain information
about vascularity of the mass; however, what is important in the
Table 2
Summary of the 22 patients with midcheek masses.
Patient
no.
Age/
Sex
Size cm FNAC Final Diagnosis Management Follow-up
month
Complication
1 F/17 1  1.2 Muscular tissue Masseter hypertrophy Botox inﬁltration 6 None
2 M/32 1.3  1.2 // Masseter hypertrophy Botox inﬁltration 6 None
3 F/76 2  1.5 Fibrolip tissue,
lymphoepithelial cells
Chronic sclerosing sialadenitis
of APGs
External 6 Temporary Facial nerve palsy
4 M/39 2.3  1 Salivary tissue VMs/ Hemangioma of APGs External previous Embolization 10 None
5 F/41 2.6  2 Fibrolip tissue Lipoma External 6 Edema, Hematoma
6 F/30 3  1.5 Blood and ﬁbrolip
tissue
VMs/Hemangioma Intraoral 14 None
7 M/51 2.9  1.3 Linf B cells APGs Scialoadenitis External 24 Temporary Facial nerve palsy,
Hematoma
8 M/11 4.1  1.7 Blood- tinged ﬂuid
without
cellular component
VMs/Hemangioma Intraoral 12 Edema, Hematoma
9 M/51 3  2.4 Lymph tissue Lipoma External 6 None
10 M/55 5.7  9.1 Fibrolip tissue Fibroma External 6 None
11 M/6 0.5  1 Neurogenic tumor Neuroﬁbroma Direct skin incision 34 Buccal branches palsy
12 F/63 1.5  0.4 Salivary tissue Fibroma of APGs Intraoral 6 None
13 F/39 5  3 Fibrolip tissue Lipoma External 6 None
14 M/53 2.4  2 Pleomorphic adenoma Pleomorphic adenoma of AGPs Intraoral 22 Hematoma
15 M/69 2.5  2.4 Fibrolip tissue APGs Scialoadenitis External 11 Temporary facial nerve palsy
16 F/20 4.2  5.3 Blood and
inﬂammatory cells
VMs Direct skin incision previous
Embolization
13 Unpleasant scar
Temporary facial nerve palsy
17 F/7 2  1 Blood- tinged ﬂuid
without
cellular component
VMs/Linfangioma Intraoral 36 Hematoma
18 F/19 1.4  2.1 // Masseter hypertrophy Botox inﬁltration 6 None
19 F/25 1.3  1 // Masseter hypertrophy Botox inﬁltration 6 None
20 F/54 2.2  1.4 Muscular tissue Intramuscular lipoma Intraoral 6 None
21 M/51 3  2.8 Fibrolip tissue Fibroma of APGs External 6 None
22 F/45 1.4  2.4 Pleomorphic adenoma Pleomorphic adenoma of AGPs External 23 Temporary facial nerve palsy,
Hematoma
Fig. 2. Typical appearance of a patient with a large venous malformation (VMs) in the
left midcheek.
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mass. Actually these lesions may be intramuscular, may arise from
APGs or may originate from midcheek vessels in general.
Magnetic Resonance imaging was extremely useful in diag-
nosing the mass as a VMs before surgery, clarifying relationships
between the mass and adjacent structures and determining the
surgical approach to the mass. Hemangiomas in the APGs had high
T2-weighted signal intensity and showed strong patchy enhance-
ment with gadolinium (Kaneko and Kanai, 2011) (Fig. 5a,b). Zhong
et al. (2012) observed small ﬂow voids on MR on both T1- and T2-
weighted images where an intramuscular vascular malformation
was present. Contrast enhanced CT scans were useful in all
remaining cases as an investigation to obtain information about the
anatomical relationships, with regard to the origin and extent of the
underlying mass. Fine-needle aspiration cytology (FNAC), which is
reliable, safe, and quick to perform, is still suggested as the ﬁrst line
diagnostic tool for a midcheek mass. In our experience we achieved
good results on diagnostic accuracy, using Doppler ultrasound, CT
scans and FNAC.
After differential diagnosis, the second important question
concerns the surgical approach to the midcheek region. Most Au-
thors focus their attention on the surgical treatment of speciﬁc
midcheek masses (APGs, VMs etc), however, they do not describe
the surgical management of the midcheek pathology in general.
The Intraoral approach ﬁrst described in 1979 was soon rejected
because it provides inadequate exposure for the control of bleeding
and preservation of facial nerve. Schmutzhard et al., 1979 proposed
a revaluation of this method as supported by active nerve moni-
toring and bipolar cautery but difﬁculties to obtain bleeding control
and to avoid Stensen’s duct damage still remain.
Direct skin incision over the mass was an ill-advised procedure.
Johnson and Spiro (1979) reported a 40% incidence of facial nerve
injury for tumors approached via a direct skin incision over the
mass (May and Schaitkin, 2003; Stajcic and Roncevic, 1990).
Fig. 3. (a) T2 weighed MRi in axial view showing Hyperintense lesion in right midcheek, (b) axial view contrast enhanced CT scan showing Hypointense lesion in right midcheek.
Fig. 4. External parotid approaches to reach midcheek area: (a) modiﬁed Blair s’ incision; (b) Face-lift-type incision; (c) Direct skin incision over a large solitary vascular mal-
formation (VMs) in left midcheek area; (d) Intraoperative pictures during removal of lipoma in the left midcheek area through an intraoral approach.
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Table 3
Post-operative complications.
Number of procedures Approach Complications Complications rate
10 External 5 50%
6 Intraoral 3 50%
2 Direct skin incision 2 100%
18 Total 10 55.5%
Fig. 5. Right midcheek hemangioma on MR examination had high T2-weighted signal intensity (a); and showed strong patchy enhancement with gadolinium (b).
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APGs pathology is the standard parotidectomy incision (Blair’s
incision or face-lift incision) (Bozzetti et al., 1999; Brusati et al.,
1987; De Maria et al., 2010; Kronenberg et al., 1988; Perzik and
White, 1992; Rodino and Shaha, 1993).
Klotz and Coniglio (Klotz and Coniglio, 2000) suggest extending
the incision superiorly into the hair bearing portion of the scalp and
inferiorly into an upper cervical crease to obtain adequate exposure
of the operative site and to obtain good bleeding and nerve control.
Low-grade APGs malignancy may be adequately dealt with by wide
excision without parotidectomy, while advanced stage disease re-
quires total parotidectomy and neck dissection.
Perzik and White (Perzik and White, 1992) commented that
managing every tumor with a formal superﬁcial parotidectomy and
full facial nerve dissection would increase morbidity with little
added beneﬁt.
According to Zheng (2012) Authors believe that VMs should be
treated with a selective embolization of blood vessels supply before
surgery; this procedure reduces the risk of bleeding and reduces
post-operative complications as in our series. Jung et al. (2010) have
suggested a new surgical procedure to treat the midcheek mass
named “parotidotomy approach”. After facial nerve trunk identiﬁ-
cation they bisected the parotid gland along the zygomatic and
buccal branches preserving the parotid gland tissue as much as
possible. In this way the mass is safely removed while protecting
the facial nerve and the Stenson’s duct, and avoiding unnecessary
parotid gland resection (McCormack et al., 1945).
An incision up to 10e15 cm long, a large wound, and a visible
scar on obvious facial areas are the common disadvantages of these
parotidectomy approaches.
The balance between the operation’s safety and the cosmetic
and minimally invasive aspects must be considered. Xie et al., 2012
ﬁrst described the results of minimally invasive endoscopic
approach for resection of a benign tumor in the accessory parotid
gland. Later, Li et al. (2013) evaluated the feasibility of a modiﬁed
endoscopic approach with minimal, and concealed, incisions for
the resection of benign tumors in the accessory parotid gland.5. Conclusions
In our series we found a signiﬁcant rate of temporary compli-
cations in all procedures performed (external, intraoral, direct skin
approach) which cause prolonged healing time and costs of care
(Table 3). Good results obtained by endoscope assisted surgery
suggest that this new approach could be a possible alternative tothe traditional approaches for the management of well selected
benign midcheek mass. Further studies are needed to increase the
knowledge of the endoscopic anatomy of the midcheek area in
order to standardize the procedure and better deﬁne the surgical
indications.Acknowledgment
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